About the Company
Adaptimmune is a biopharmaceutical company that develops T cell therapies against cancer. The company was founded in 2008 in the UK with links to both Oxford University and the University of Pennsylvania. It has headquarters in Philadelphia and Milton Park. In August 2024, the US Food and Drug Administration granted accelerated approval to Adaptimmune's Tecelra, a therapy against a rare form of cancer. Tecelra is the first T cell therapy to be approved for use against a solid tumor.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Adaptimmune Therapeutics PLC
Adaptimmune Faces Nasdaq Delisting Notice Amid Compliance Issues
Adaptimmune Therapeutics ( ($ADAP) ) has shared an announcement. Adaptimmune Therapeutics plc, a company involved in the biotechnology industry, ...
Adaptimmune Reports Growth and Strategic Moves in Q2
Adaptimmune Therapeutics Plc. ( ($ADAP) ) has released its Q2 earnings. Here is a breakdown of the information Adaptimmune Therapeutics Plc.
Adaptimmune Reports Q2 Financial Results and Provides Business Update
Q2 Tecelra sales of $11.1m with 16 patients invoiced represents >150% growth vs Q1 2025Entered into a definitive agreement ...
Adaptimmune Sales Jump 59 Percent
Key Points Earnings per share (GAAP) for Q2 2025 beat estimates by 52.4%, coming in at $(0.02) compared to the expected $(0.042). Revenue (GAAP) was $13.7 million for Q2 2025, outpacing the $8.6 ...
Adaptimmune Therapeutics PLC ADR Company & People | ADAP | Barron's
Adaptimmune Therapeutics Plc is commercial-stage cell therapy company, which focuses on providing novel cell therapies to people with cancer. Its clinical pipeline includes Afami-cel, Lete-cel ...
How Much Are Adaptimmune Therapeutics plc (NASDAQ:ADAP) Insiders Taking ...
Insiders own 1.2% of Adaptimmune Therapeutics shares, worth about US$8.2m, according to our data. Overall, this level of ownership isn't that impressive, but it's certainly better than nothing!
Adaptimmune Therapeutics plc (ADAP) CEO James Noble on Q2 2019 Results ...
Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q2 2019 Results Conference Call August 1, 2019 8:00 AM ETCompany ParticipantsJuli Miller - IRJames Noble - ...
What Makes Adaptimmune Therapeutics PLC (ADAP) a New Strong ... - Nasdaq
Adaptimmune Therapeutics PLC (ADAP) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in ...
Adaptimmune Therapeutics PLC: Adaptimmune Reports Q2 Financial Results and Provides Business Update
Q2 Tecelra sales of $11.1m with 16 patients invoiced represents >150% growth vs Q1 2025Entered into a definitive agreement for the sale of TECELRA, lete-cel, afami-cel, and uza-cel cell therapies to U ...
Similar Companies
Loading the latest forecasts...